Details
Category: Volume 08 Issue 10 October 2020
Hits: 960

Title: A General Audit of Adenocarcinoma Lung Cases Treated At JK Cancer Institute Kanpur between January 2018 to December 2019

Authors: Md Aqueel, Mayank Kumar Gautam, S.N. Prasad, M W Raza, Pramod Kumar Singh

 DOI: https://dx.doi.org/10.18535/jmscr/v8i10.03

Abstract

Introduction: Lung adenocarcinoma is a subtype of non-small cell lung cancer (NSCLC). Lung adenocarcinoma is categorized as such by how the cancer cells look under a microscope. Lung adenocarcinoma starts in glandular cells, which secrete substances such as mucus, and tends to develop in smaller airways, such as alveoli(1,2,3,4). Gefitinib is a small molecule tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR)(5). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers (NSCLC) obtaining objective response when treated with gefitinib harbour activating mutations in the EGFR gene. Consequently, EGFR mutation has been widely studied, together with other molecular characteristics, as a potential predictive factor for gefitinib efficacy(6,7,8,9,10,11)

Aim: To Compare the overall survival, time to disease progression and toxicity between two chemotheraupetic regimen.

Material And Methods: Single institution retrospective study 2018, 2019 in patients who received gefitinib, gemcitabine+cisplatin, gemcitabine+carboplatin, paclitaxel+carboplatin based chemotheraupetic regimen. A total 75 patients were identified. of whom 19 patients received tab gefitinib,7 received pacli+carbo,1 received RT f/b pacli+carbo,1 patient received pacli+carbo f/b RT,2 patient received pacl+carbo f/b gefitinib,6 patient received gem+carb f/b gefitinib,2 received palliative RT f/b gefitinib,1 patient received gefitinib f/b methotrexate,1 patient received gefitinib f/b pacli+carbo,3 patient received gefitinib f/b RT,1 patient received gem+cis,1 patient received gem+cis f/b gem+carb,1 patient received gem+cis f/b gefitinib,1 patient received bevaci+gem+carb,1 patient received erlotinib,3 patient received palliative RT,1 patient received bevaci+gem+carb f/bgem+carb f/b pacli+carb f/b gem+carb f/b gefitinib

Results: We observed the overall survival, time to progression were better in gefitinib arm. No major acute toxicities seen in both arm

Conclusion: Gefitinib based chemotherapy provide better overall survival and increased time to disease progression and advantage of oral dosing thus facilitating drug delivery and patient compliance

Keywords: Gefitinib, adenocarcinoma lung.

References

  1. What is Non-Small Cell Lung Cancer? American Cancer Society website.  https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html. Revised May 16, 2016. Accessed June 10, 2019.
  2. NCI Dictionary of Cancer Terms. National Cancer Institute website.  http://www.cancer.gov/dictionary. Accessed June 10, 2019.
  3. Non-Small Cell Lung Cancer Treatment (PDQ®)—Patient Version. National Cancer Institute website.  https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq. Updated May 31, 2019. Accessed June 7, 2019.
  4. Chen Z, Fillmore M, et al. Non-small cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014 Aug; 14(8): 535-546. doi: 10.1038/nrc3775.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712844/. Accesed June 10, 2019.
  5. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183–232. [PubMed] [Google Scholar ]
  6. Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol. 2006;24:3340–6. [PubMed] [Google Scholar]
  7. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005;23:8081–92. [PubMed][Google Scholar]
  8. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362:2380–8. [PubMed] [Google Scholar]
  9. Tamura K, Okamoto I, Kashii T, Negoro S, Hirashima T, Kudoh S, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: Results of the West Japan Thoracic Oncology Group trial (WJTOG0403) Br J Cancer. 2008;98:907–14. [PMC free article][PubMed] [Google Scholar]
  10. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008; 26:2442–9. [PubMed] [Google Scholar]
  11. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23:2513–20.  [PubMed] [Google Scholar].

Corresponding Author

Md Aqueel

Junior Resident Doctor Second Year, J.K. Cancer Institute Kanpur